TFA Therapeutics, Inc.
- Ticker
- RAJAF
- CIK
- 1885680
- Industry
- Medicinal Chemicals & Botanical Products
- Formerly
- Cordyceps Sunshine Biotech Holdings Co., Ltd.
Financials 4
- NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2025
- NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2024
- NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2023
- NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2022
Prospectus 6
- 424B4 Prospectus filed pursuant to Rule 424(b)(4)
- DRSLTR Correspondence Related to Draft Registration Statement
- DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
- DRSLTR Correspondence Related to Draft Registration Statement
- DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
- DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Other 28
- 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- 20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
- 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- 20-F/A Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
- 20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
- 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
- UPLOAD Letter (PDF)
- CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.